Home / fashion / TOP9：美宝莲Angelababy直播营销2小时卖10000只口红曹淼(年轻盟创始人、人人CMO)：美宝莲运用AB来做的电商直播，堪称一次非常完美的营销创新，虽然之后也有诸多品牌做了更多电商直播的尝试，也有效果非常惊人的案例，但因为美宝莲作为国际品牌，较早的意识到并运用直播这种新形态的社交触达方式，以及将明星与电商平台进行创造性的结合，所以标杆意义非凡。
As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.
A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).
advertisement
In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.
Get unlimited access to award-winning journalism and exclusive events.
